Asia Study Group of Prostate Cancer (A-CaP Study)

Overview

This study will target patients who have received a histopathological diagnosis of prostate cancer and who are undergoing treatment in various forms, including active PSA surveillance, surgical treatment, radiotherapy, endocrine therapy, and chemotherapy. The study will survey information about the patient at time of diagnosis, clinical staging, details of initial treatment, status of disease progression, and prognosis at the end point of the study. The purpose of the study is to clarify distribution of staging, the actual status of treatment choices and treatment outcomes.

Full Title of Study: “Research Concerning Background Factors at Time of Diagnosis and Initial Treatment and Treatment Progress Cancer Patients in Asia”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 2019

Detailed Description

The A-CaP will collect information in a linkable anonymized format from all medical institutions in Asian countries participating in the study and will engage in data analysis. J-CaP which has previous experience of engaging in a similar study in 2010 wll be a sponsor for A-CaP study, the aggregated results of which have been reported. The registration period for this study will be three years followed by 7 years of follow-up study, and research will be implemented across a wider range of Asian countries, with new institutions participating for the purposes of this study. As this study will be an observational study the acquisition of data will be relatively simple, and as the content of the study will be almost identical to the study conducted by J-CaP in 2010, a system for research implementation is already established at J-CaP.

Arms, Groups and Cohorts

  • Prostate Cancer
    • About 20,000 patients who have received a histopathological diagnosis of prostate cancer from ten countries in Asia.

Clinical Trial Outcome Measures

Primary Measures

  • Patients background at time of diagnosis of prostate cancer, treatment progress and prognosis with the reason for progression and subsequent treatment methods
    • Time Frame: three years
    • The following items are examined for primary outcome measure. Patient background which is represented by month and year of birth; height and weight; ethnicity and family history; medical history; and name of condition/disease for which currently receiving treatment at hospital. Information pertaining to prostate cancer which is represented by PSA value at time of prostate cancer diagnosis and Gleason score. Prognosis information which is survival or death at end point of the Study.

Secondary Measures

  • Patient QOL measured by SF-36 during treatment by comparison with A-Cap data and data in the United States and Australia
    • Time Frame: three years
    • The short form 36 (SF-36) is used for an evaluation indicator of patient QOL. SF-36 includes the following eight elements. Physical functioning Role functioning Physical Bodily pain General health Vitality Social functioning Role functioning emotional Mental health More detailed questions are prepared under the above each eight element, which a score is produced for a quantitative outcome of the patients QOL.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients who have received a histopathological diagnosis of prostate cancer between January 1,2016,and December 31,2018. – Patients who, having received a diagnosis within the abovementioned period, began initial treatment for prostate cancer(including active surveillance). – Patients who are either hospitalized as outpatients. Exclusion Criteria:

• Patients for whom information about the time of diagnosis, including histopathological diagnosis, cannot be acquired.

Gender Eligibility: Male

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Japan Study Group of Prostate Cancer
  • Provider of Information About this Clinical Study
    • Principal Investigator: Hideyuki Akaza, Professor – Japan Study Group of Prostate Cancer
  • Overall Official(s)
    • Hideyuki Akaza, M.D., Ph.D., Study Director, J-CaP

References

Onozawa M, Hinotsu S, Tsukamoto T, Oya M, Ogawa O, Kitamura T, Suzuki K, Naito S, Namiki M, Nishimura K, Hirao Y, Akaza H. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan. Jpn J Clin Oncol. 2014 Oct;44(10):969-81. doi: 10.1093/jjco/hyu104. Epub 2014 Aug 6.

Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009 Sep 10;27(26):4306-13. doi: 10.1200/JCO.2008.21.5228. Epub 2009 Aug 10.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.